

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. - 36 (Canceled)

37. (Withdrawn) A method for selecting optimized glycosylated monoclonal antibodies, wherein said antibodies have less than 50% of G0F and G1F glycan structure on their Fcγ, comprising:

a) bringing into contact a CD16 expressing effector cells of the immune system, which may or may not be transformed, in a reaction medium in the presence of an antibody and the antigen for said antibody,

b) measuring the amount of at least one cytokine produced by the CD16 expressing cell, and

c) selecting antibodies for which the level of said cytokine produced is increased by more than 100% compared with the control in the absence of antibody or in the presence of a given antibody as a negative reference.

38. (Currently amended) A method for selecting ~~evaluating the effectiveness of a~~ monoclonal ~~or polyclonal~~ antibody, comprising:

a) bringing a CD16-transformed ~~receptor-expressing~~ effector cell Jurkat ~~cells,~~ which may be transformed so as to express the CD16 receptor, into contact in a reaction medium with the ~~the~~ [[a]] monoclonal ~~(MoAb)~~ ~~or polyclonal~~ antibody and the ~~the~~ [[an]] antigen for said antibody, ~~the antibody being activated by the antigen, and the antigen being different from the CD16, and~~

b) measuring the amount of IL-2 ~~at least one~~ cytokine released, ~~produced by the~~ CD16 ~~expressing cell,~~ and

c) selecting an antibody for which the level of said IL-2 release is increased by more than 100% compared with a negative control, performing an ADCC assay, wherein the measurement of the amount of IL-2 is linearly correlated to the CD16-specific with an ADCC (antibody-dependent cellular cytotoxicity)-type activity, and wherein the negative control is an antibody of the same specificity produced by CHO cells or the absence of the antibody.